Ropivacaine, as a representative of the long-acting local anesthetics (LAs), is available for the spinal anesthesia, and its duration is 1.6-6 h (Z S et al., 2012). However, some clinical studies have shown that ropivacaine may induce severe neurotoxic side effects after intravenous injection in recent years. Some experiments have also demonstrated that ropivacaine induces neurotoxicity after the long-term exposure to ropivacaine at a high-concentration (A B et al., 2017;S C and S S, 2018;W Z and BM G, 2008). Since Yamashita et al. first reported the neurotoxicity of ropivacaine (Yamashita A et al., 2003), many studies have been conducted to explore and compare the neurotoxicity of LAs commonly used in the clinical practice, including lidocaine, and bupivacaine (Byram SC et al., 2020;Lirk P et al., 2008). Although it had been reported that ropivacaine has the least neurotoxicity among the LAs tested, increasing attention has been paid to the safety of ropivacaine (Yamashita A,Matsumoto M,Matsumoto S,Itoh M,Kawai K and Sakabe T, 2003). Currently, the clinical dosage of ropivacaine is still controversial. It has been reported that injection of high-dose ropivacaine into the epidural space or subarachnoid space can shorten the onset time and increases the motor block effect (Guryay D et al., 2008), while other studies have shown the increased risk of neurotoxicity after exposure to a high-dose ropivacaine (Takenami T et al., 2002). Hence, it is important to investigate the mechanism underlying the ropivacaine induced neurotoxicity, which is helpful for the development of preventive measures and will make the spinal anesthesia safer.
The mechanism of ropivacaine induced neurotoxicity is unclear, and some studies reported it is related to cell apoptosis. Our previous study also revealed that ropivacaine increased apoptosis via up-regulating Fas / Fasl expression in PC12 cells (Zeng Y,Wang R,Bian Y,Chen W and Peng L, 2019), which were also confirmed by Wang et al. (S W et al., 2019). As we know, apoptosis may execute in two pathways: the death receptor pathway and the mitochondrial pathway (Zeng Y,Wang R,Bian Y,Chen W and Peng L, 2019). The death receptor pathway is represented by the up-regulation of Fas/Fasl expression, and the mitochondrial pathway is characterized by the mitochondrial dysfunction. In addition to inducing neurotoxicity through the death receptor pathway, ropivacaine has also been proved to cause neuronal damage by impairing the mitochondrial function. Niu et al. reported ropivacaine affected the mitochondrial biogenesis of neuronal cells by reducing the mitochondrial mass and impairing the mitochondrial respiratory rate via suppressing PCG-1a (Z N et al., 2018). In the present study, our findings confirmed that apoptosis played an important role in the ropivacaine induced neurotoxicity. At first, the cell viability was detected after treatment with different concentrations of ropivacaine. Results showed that ropivacaine decreased the cell viability in a dose-dependent manner. In addition, ropivacaine reduced the protrusions of PC12 cells and cells became round after ropivacaine treatment, which means the cell death increases. In order to determine the cell death pathway induced by ropivacaine, we analyzed the change of cell cycle and apoptosis of ropivacaine-treated PC12 cells using flow cytometry, and results showed that ropivacaine arrested the PC12 cells in G0/G1 phase and increased cell apoptosis. The mRNA and protein expressions of genes regulating the cell cycle and apoptosis were further detected in cells after ropivacaine treatment. p21 is one of those genes that block the cell cycle progression (El-Deiry WS, 2016), and p21 expression increased in the PC12 cells with an increase of ropivacaine concentration. On the contrary, CyclinE1 and CDK4 are the key genes for the maintenance of normal cell cycle progression (Lim S and Kaldis P, 2013;Schade AE et al., 2019;Xu W and McArthur G, 2016). Our results showed that the expression of CyclinE1 and CDK4 in PC12 cells significantly reduced after ropivacaine treatment. Bax and Caspase 3 are the pro-apoptotic proteins in the mitochondrial pathway, and BCL-2 is an anti-apoptotic protein. Our results showed ropivacaine increase the expression of Bax and Caspase 3 in the PC12 cells and inhibit the expression of Bcl-2, which suggests that the mitochondrial apoptosis pathway is involved in the ropivacaine induced neurotoxicity.
To further clarify the effects of ropivacaine on the cellular oxidative stress and mitochondria, the reactive oxygen species (ROS) generation was assessed in cells before and after ropivacaine treatment. Our results showed that the ROS increased with the increase in the concentration of ropivacaine. Similarly, the contents of MDA and LDH also increased significantly, while the level of SOD decreased after ropivacaine treatment. These suggest ropivacaine induces cellular oxidative stress in PC12 cells. Those results were consistent with those reported by Chen et al (Chen Y,Yan L,Zhang Y and Yang X, 2019). Next, the mitochondria function was examined in PC12 cells treated with ropivacaine. Our results confirmed that ropivacaine induced cell mitochondrial dysfunction, which was mainly manifested the decreased of MMP and the ratio of mtDNA / nDNA. Those results were also confirmed by other studies (Y C et al., 2019;Z N,J T,Y R and W F, 2018).
On the basis above findings, we further investigated the role of STAT3 in the ropivacaine induced apoptosis. STAT3 was first described as a transcriptional enhancer of acute-phase genes activated by IL-6, which mediated extracellular signals such as cytokines and growth factors through interacting with polypeptide receptors on the cell surface(You L et al., 2015). The canonical STAT3 signaling becomes transcriptionally activated primarily by tyrosine phosphorylation (Tyr705). Activated STAT3 translocate to the nucleus, and binds to sequence-specific DNA elements for consequent transcription of target genes(Cui P et al., 2020). The canonical STAT3 pathway has been demonstrated to promote tumor development(Fathi N,Rashidi G,Khodadadi A,Shahi S and Sharifi S, 2018). The non-canonical STAT3 signaling is represented by serine phosphorylation (Ser727), and STAT3 phosphorylated at Ser727 functions to rescue the impaired mitochondrial function after exposure to the stimuli(Srivastava J and DiGiovanni J, 2016). When apoptosis is induced via the mitochondrial pathway, the non-canonical STAT3 signaling is activated to further protect cells against apoptosis. Except for the non-canonical pathway, STAT3 has been shown to regulate the mitochondrial function by transporting to the mitochondria (mitoSTAT3), which is also dependent on serine phosphorylation (Ser727) (Szczepanek K,Chen Q,Derecka M,Salloum FN,Zhang Q,Szelag M,Cichy J,Kukreja RC,Dulak J,Lesnefsky EJ and Larner AC, 2011;Yang R and Rincon M, 2016). As expected, ropivacaine inhibited the activation of STAT3 by down-regulating the expression of p-STAT3 (Ser727) and decreased the expression of upstream genes of STAT3. To further investigate the effect ropivacaine on mitoSTAT3 expression, the p-STAT3 (Ser727) expression was detected in the mitochondrial fraction and cytoplasmic fraction, which was used to determine that the mitoSTAT3 translocation in PC12 cells Results showed that mitoSTAT3 translocation was inhibited by ropivacaine. We also confirmed this by immunofluorescence staining, the co-localization of p-STAT3 (Ser727) in the mitochondria was significantly reduced after ropivacaine treatment. The anti-apoptotic effect of mitoSTAT3 has been demonstrated in many studies. Li et al. reported that the STAT3 activation is key for the ischemic postconditioning, and the increased of mitoSTAT3 can protect the cardiomyocytes against mitochondrial dysfunction (Li H et al., 2016). Zhang et al. reported Serine 727 (Ser727) phosphorylation of STAT3 plays a role in the regulation of mitochondrial respiration(Zhang G et al., 2018). In addition, mitoSTAT3 translocation can improve the oxidative phosphorylation and inhibit ROS generation during reperfusion. As we know, STAT3 activation depends on the phosphorylation of its hydrophobic domain, our results showed that ropivacaine could bind to the hydrophobic domain of STAT3, and this phosphorylation was inhibited, which confirms above findings. At last, we compared the levels of apoptosis and p-STAT3 (Ser727) expression in the spinal cord with the treatment of different concentrations of ropivacaine. The results showed that ropivacaine increased the apoptosis of the spinal cord in a dose-dependent manner, and the expression of p-STAT3 (Ser727) decreased significantly after ropivacaine treatment. This indicates that there was a negative relationship between p-STAT3 expression and apoptosis in the spinal cord. The above findings indicate ropivacaine can induce the neurotoxicity by promoting apoptosis via down-regulating STAT3 phosphorylation.